AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
The Role of Pathogenic Gene Variants in Breast Cancer
There's a goal to develop therapies that are going to target the specific mutation that a cancer cell might have. The main one that's really come into clinical practice is in the setting of using PARP inhibitors for tumors that have brachia mutations, so BRC mutations. A person who does not have a germline variant in the brachia gene might spontaneously develop a cancer where the cancer cell has gotten a somatic mutation in thebrachia gene. Regardless of how it got that mutation, a cancer cell that has a brachia mutation can't repair double-stranded DNA breaks.